🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
23/01/2018 53,70 57,40 53,50 57,00 +6,15% 7,26% 57.276
22/01/2018 53,70 54,50 52,70 53,70 +1,90% 3,35% 32.656
19/01/2018 53,40 53,80 52,10 52,70 -0,57% 3,18% 32.673
18/01/2018 54,90 55,00 52,30 53,00 -3,46% 4,92% 140.438
17/01/2018 55,00 56,50 54,00 54,90 -1,08% 4,55% 213.148
16/01/2018 54,00 56,70 53,60 55,50 +2,21% 5,74% 142.236
15/01/2018 56,00 57,20 53,50 54,30 -2,86% 6,61% 52.211
12/01/2018 51,20 56,30 50,80 55,90 +12,70% 10,74% 74.708
11/01/2018 50,50 50,60 49,00 49,60 -2,17% 3,17% 47.990
10/01/2018 52,50 52,50 50,50 50,70 +0,40% 3,81% 76.583
09/01/2018 49,80 52,50 49,25 50,50 +1,00% 6,53% 99.219
08/01/2018 49,60 52,20 48,80 50,00 +2,46% 6,85% 125.045
05/01/2018 48,90 51,50 48,80 48,80 -1,41% 5,52% 41.805
04/01/2018 52,00 52,40 48,80 49,50 -6,25% 6,92% 62.489
03/01/2018 53,70 53,90 51,70 52,80 -2,22% 4,10% 27.983
02/01/2018 53,50 54,30 52,70 54,00 +2,82% 2,99% 22.388
29/12/2017 52,01 52,79 50,50 52,52 +0,00% 4,40% 31.490
28/12/2017 52,99 53,45 51,07 52,52 -0,89% 4,49% 60.946
27/12/2017 50,00 54,50 49,25 52,99 +8,10% 10,50% 89.571
22/12/2017 47,57 49,88 47,57 49,02 +3,05% 4,86% 180.922
21/12/2017 48,25 48,50 46,95 47,57 -1,90% 3,21% 22.206
20/12/2017 48,05 49,00 46,87 48,49 +1,30% 4,43% 98.059
19/12/2017 49,10 50,50 45,96 47,87 -2,31% 9,25% 75.627
18/12/2017 48,50 49,54 47,01 49,00 +1,26% 5,22% 292.308
15/12/2017 50,94 50,94 45,06 48,39 -9,55% 11,54% 192.172
14/12/2017 45,00 57,48 44,41 53,50 +19,45% 29,04% 531.398
13/12/2017 45,50 46,40 43,67 44,79 -2,63% 6,00% 525.897
12/12/2017 42,25 48,16 39,40 46,00 +16,75% 20,73% 647.182
11/12/2017 27,72 41,14 27,72 39,40 +56,35% 48,41% 477.607
08/12/2017 24,99 25,71 24,98 25,20 +1,74% 2,92% 68.947